D. Samba Reddy, Ph.D., R.Ph.
8447 State Highway 47
2008 Medical Research and Education Building
Bryan, TX 77807-3260
- Ph.D., Pharmacology, Panjab University Chandigarh (1998)
- R.Ph, Pharmacy, Texas State BOP, Austin, Texas.
- Postdoctoral Fellow, National Institutes of Health, Bethesda, Maryland.
- Fellow, American Association for the Advancement of Science (AAAS)
- Fellow, American Association of Pharmaceutical Scientists (FAAPS)
- Contributing Editor, Epilepsy Currents
- Chartered Member, NIH Study Section CNNT - Clinical Neuroplasticity and Neurotransmitters
- Editor-in-Chief, International Journal of Pharmaceutical Sciences and Nanotechnology
- Review Editor, Frontiers in Neuroscience & Frontiers in Pharmacology
- Delegate Member, The United States Pharmacopoeia (USP)
- Registered Pharmacy Practitioner, Texas, United States
Translational Pharmacology and Neurotherapeutics of Epilepsy and Brain Disorders
Dr. Reddy has been in the pharmacology research field for over 23 years. His lab is mainly focused on drug development for epilepsy and brain disorders. Epilepsy and seizure disorders affect about 50 million people worldwide, including thousands of veterans and civilians in the US. He directs a productive multidisciplinary group utilizing pharmacological, electrophysiological, histological, mass spectrometric, and transgenic techniques. Current projects in the Reddy lab are centered on elucidating the molecular pathophysiology of, and developing mechanism-based novel drug therapies for, epileptogenesis, status epilepticus, post-traumatic epilepsy, post-stroke epilepsy, and chemical neurotoxicity. He has a long standing interest in neurosteroids as novel anticonvulsants. Dr. Reddy was instrumental in discovering many preclinical models, mechanism-based treatment strategies, and novel medicines for complex brain disorders. His lab has been conducting pioneering investigations on neurosteroid interactions at synaptic and extrasynaptic GABA-A receptors. His research has been continuously funded by the NIH for over 12 years. He is the principal investigator of an NIH Cooperative Agreement U01 project focusing on novel treatments for organophosphate and chemical nerve agent intoxication. He directs a DOD project on post-traumatic epilepsy after traumatic brain injury. He teaches both medical and graduate courses on human pharmacology and pharmacodynamics and mentors many undergraduates and doctoral & postdoctoral trainees. Dr. Reddy has published over 150 papers and book-chapters (h-index 40), which are available worldwide (http://orcid.org/0000-0003-2735-9550).
- Carver CM, Wu X, Gangisetty O and Reddy DS (2014). Perimenstrual regulation of extrasynaptic delta-containing GABA-A receptors mediated tonic inhibition and neurosteroid sensitivity. Journal of Neuroscience 34(43):14181-97.
- Reddy DS. Role of hormones and neurosteroids in epileptogenesis. Frontiers in Cellular Neuroscience 2013, 7(115): 1-20.
- Reddy DS (2014). Neurosteroids and their role in sex-specific epilepsies. Neurobiology of Disease 72(Pt B):198-209.
- Carver CM and Reddy DS. Neurosteroid interactions with synaptic and extrasynaptic GABA-A receptors: Regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology 2013, 230(2):151-188.
- Wu X, Gangisetty O, Carver CM and Reddy DS. Estrous cycle-regulation of extrasynaptic δ-containing GABA-A receptor-mediated tonic inhibition and limbic epileptogenesis. J Pharmacol Exp Therap 2013, 346:146-160.
- Reddy DS and Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. International Journal of Molecular Sciences 2013, 14:18284-18318.
- Reddy DS. The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Reviews of Clinical Pharmacology 2013, 6(3):271-288.
- Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Hormones & Behavior 2013, 63: 254–266.
- Reddy DS and Ramanathan G. Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Epilepsy & Behavior 2012, 25:92-97.
- Reddy DS. Novel new drug approvals in 2011: A succinct analysis of drug discovery trends in the United States. Int J Pharm Sci Nanotech. 2012, 5: 1661-1665.
- Reddy DS, Gould J, and Gangisetty O. A mouse kindling model of perimenstrual catamenial epilepsy. J Pharmacol Exp Therap 2012, 341:784-793.
- Reddy DS. Current drug shortages in the United States. Pharma Times 2012, 44 (6):22-25.
- Reddy DS. Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Frontiers in Neuroendocrinology 2011 (vol 2); article 38, pp 1-11.
- Reddy DS (author). Pharmacy Quiz. 2nd Edition. PBS Publishers, Hyderabad 2012, pages 1-1150. **Major review book for pharmacy graduate and board exams**
- Wu X and Reddy DS. Integrins as receptor targets for neurological disorders. Pharmacology & Therapeutics 2012, 134:68-81.
- Reddy DS and Mohan A. Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. Journal of Neuroscience 2011;31 650-658.
- Reddy DS, Gangisetty O. and Briyal S. Disease-modifying activity of progesterone in the hipocampus kindling model of epileptogenesis. Neuropharmacology 2010, 59:573-581.
- Reddy DS. Neurosteroids: Endogenous role in the human brain and therapeutic potentials. Progress in Brain Research 2010, 186: 113-137.
- Gangisetty O. and Reddy DS. Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of PR-independent Egr3 pathway. Neuroscience 2010, 170: 865-880.
- Reddy DS and Jian K. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABA-A receptors. J Pharmacol Exp Therap 2010, 334:1031-1041.
- Reddy DS and Rogawski MA. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Research 2010, 89:254-260.
- Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 2010, 3(2):183-192.
- Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Research 2009, 85 (1): 1-30.
- Gangisetty O and Reddy DS. The optimization of TaqMan real-time RT-PCR assay for transcriptional profiling of GABA-A receptor subunit plasticity. Journal of Neuroscience Methods 2009, 181(1):58-66.
- Reddy DS and Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6(2):392-401.
- Reddy DS. Mass spectrometric quantification and physiological-pharmacological activity of androgenic neurosteroids. Neurochemistry International 2008; 52(4-5):541-553.
- Reddy DS and Zeng YC. Effect of neurosteroid withdrawal on spontaneous recurrent seizures in a rat model of catamenial epilepsy. FASEB Journal 2007, 21(6): A1179-A1180.
- Rao MV, Hattiangady B, Reddy DS, and Shetty AK. Hippocampal neurodegeneration, spontaneous seizures and mossy fiber sprouting in F344 rat model of temporal lobe epilepsy. Journal of Neuroscience Research 2006, 83(6):1088-105.
- Reddy DS. Physiological role of adrenal deoxycorticosterone-derived neuroactive steroids in stress-sensitive conditions. Neuroscience 2006, 138:911-920.
- Reddy DS, O’Malley BW, and Rogawski MA. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 2005, 48:14-24.
- Reddy DS, Chien B, and Ramu K. A high-performance liquid chromatography-tandem mass spectrometry assay of the androgenic neurosteroid 3a-androstanediol in plasma. Steroids 2005, 70:879-885.
- Reddy DS, Castenada DA, O’Malley BW, and Rogawski MA. Antiseizure activity of progesterone and neurosteroids in progesterone receptor knockout mice. The Journal of Pharmacology and Experimental Therapeutics 2004, 310: 230-239.
- Reddy DS and Woodward R. Ganaxolone: a prospective overview. Drugs of the Future 2004, 29:227-242.
- Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends in Pharmacological Sciences 2003, 24: 103-106.